ABRILADA Drug Profile

Summary for Tradename: ABRILADA

High Confidence Patents:	0
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ABRILADA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ABRILADA Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ABRILADA Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for ABRILADA (Ravulizumab)

Last updated: April 14, 2026

What is ABRILADA (Ravulizumab)?

ABRILADA, marketed as Ravulizumab, is a complement inhibitor developed by Alexion Pharmaceuticals for the treatment of rare and severe diseases involving complement system dysregulation. It is approved primarily for conditions like paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Market Size and Growth Drivers

Current Market Valuation

• The global complement inhibitor market was valued at approximately USD 1.2 billion in 2021.
• It is projected to reach USD 3.4 billion by 2028, with a compound annual growth rate (CAGR) of 16.4% from 2022 to 2028 (Research and Markets, 2022).

Key Drivers

• Rare Disease Focus: Growing acceptance and reimbursement for orphan drugs improve market potential.
• Expanding Indications: Clinical trials explore Ravulizumab’s use in conditions like neuromyelitis optica, hemolytic anemia, and other complement-mediated disorders.
• Increased Diagnosis: Advances in diagnostics lead to higher identification of complement-related diseases.
• Competitive Landscape: Eculizumab (Soliris) from Alexion is a major competitor; Ravulizumab offers a less frequent dosing alternative, influencing its market appeal.

Competitive Positioning

Key Competitors

Drug	Manufacturer	Indications	Dosing Frequency	Market Share (2022)
Ravulizumab	Alexion/ AstraZeneca	PNH, aHUS, gMG	Every 8 weeks	58% (Estimate)
Eculizumab	Alexion	PNH, aHUS, Others	Weekly or bi-weekly	42% (Estimate)

Differentiation

Ravulizumab’s quarterly dosing improves patient adherence compared to eculizumab’s weekly or bi-weekly schedule. This reduces administration costs and increases patient convenience, positioning it favorably in the market landscape.

Revenue Trajectory

Historical Revenue

• Alexion’s total revenues from Ravulizumab were approximately USD 600 million in 2021, accounting for 55% of the company’s total sales (Alexion Annual Report, 2022).

Projected Revenue Growth

• The drug’s annual sales are expected to reach USD 1.2 billion by 2025, driven by increased patient enrollment and expanded indications.
• Growth rates assume stable market share, increased reimbursement, and new indication approvals.

Sources of Revenue Expansion

• Geographic Penetration: Entry into emerging markets, notably Asia-Pacific, which could contribute an additional 15-20% of revenue by 2025.
• Indication Expansion: Pivotal trials for aHUS and gMG are ongoing, with potential approvals expected between 2023 and 2025.
• Pricing Strategies: Premium pricing maintained on the basis of orphan drug status and administration benefits.

Market Challenges and Risks

• Regulatory Uncertainty: Post-pandemic regulatory pathways may slow approvals or increase requirements.
• Pricing Pressures: Payor pushback against high-cost therapies could restrict accessible patient populations.
• Competition: Eculizumab’s biosimilars and other complement inhibitors emerging could erode market share.
• Manufacturing Disruptions: Biologic production complexity presents risks related to scalability and quality control.

Regulatory and Patent Landscape

• Patent Protection: Patents on Ravulizumab extend into the 2030s, preventing biosimilar entry.
• Regulatory Approvals: Approved in the US (2018), EU (2019), and Japan (2020); ongoing filings in other regions.

Financial Outlook Summary

Year	Revenue (USD Billion)	CAGR	Key Assumptions
2022	0.6	—	Existing sales, steady access
2023	0.8	33%	Expanded indications, new markets
2024	1.0	25%	Increased diagnosis, price stabilization
2025	1.2	20%	Broad market adoption, reimbursement growth

Key Takeaways

• ABRILADA’s market relies on a limited number of rare disease indications, but its advantages in dosing schedule position it favorably.
• Revenues are projected to grow at a compound rate of approximately 20-25% annually until 2025.
• Market expansion depends on geographic penetration, indication approvals, and reimbursement policies.
• Competition from biosimilars and new complement inhibitors remains a primary risk.
• Patent protections and ongoing clinical trials will influence long-term revenues beyond 2025.

FAQs

1. What are the main indications for ABRILADA?

Primarily PNH, aHUS, and generalized myasthenia gravis.

2. How does Ravulizumab differ from Eculizumab?

Ravulizumab is administered every 8 weeks, whereas Eculizumab typically requires weekly or bi-weekly dosing.

3. What is the outlook for revenue growth in the next five years?

Projected CAGR of 20-25%, reaching USD 1.2 billion by 2025.

4. What risks could impact the market for ABRILADA?

Regulatory delays, pricing pressures, biosimilar competition, and manufacturing challenges.

5. When are new indications expected to gain regulatory approval?

Ongoing trials targeting gMG and other complement-mediated diseases are expected to yield data between 2023 and 2025.

---

References

1. Research and Markets. (2022). Global complement inhibitor market forecast.
2. Alexion Pharmaceuticals. (2022). Annual report.
3. European Medicines Agency. (2019). Approval of Ravulizumab.
4. U.S. Food and Drug Administration. (2018). FDA approval documentation.